Yinma Jiedu Granule attenuates LPS-induced acute lung injury in rats via suppressing inflammation level.

ETHNOPHARMACOLOGICAL RELEVANCE: Yinma Jiedu Granule (YMJD) is a traditional Chinese patent medicine (CPM), which has been proved to have anti-inflammatory effects and therapeutical effects on obstructive pulmonary disease.

AIM OF STUDY: The purpose of the current investigation is to find out if YMJD can alleviate acute lung injury (ALI) induced by lipopolysaccharide (LPS) in rats and its underlying mechanisms.

MATERIALS AND METHODS: Rats were treated with either vehicle or YMJD for 14 consecutive days, and two hours after the last administration, the rat model of ALI was induced by the intratracheal instillation of LPS. HPLC was applied for the fingerprint analysis of YMJD. The efficacy and molecular mechanisms were investigated.

RESULTS: The results showed that treatment with YMJD improved the general state of rats, reduced weight loss and serum lactate (LA) levels, attenuated pulmonary edema and pathological damage of the lung tissue. Moreover, we found that YMJD effectively decreased the infiltration of white blood cells (WBC), lymphocyte (LYM), mononuclear cells (MON) and neutrophils (NEUT) in bronchoalveolar lavage fluid (BALF), reduced the concentrations of tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) in the lung and inhibited inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) expression. We also found that YMJD could increase the activity of superoxide dismutase (SOD) and reduce the malondialdehyde (MDA) level in the lung tissue of rats. By employing RNA-sequencing, we have identified that JAK2/STAT1 is an important pathway that is involved in the lung protection of YMJD, and further western blot assay verified that YMJD could effectively inhibit the activation of the JAK2/STAT1 pathway.

CONCLUSIONS: YMJD could attenuate LPS-induced ALI through suppressing inflammation and oxidative stress in the lung tissue of rats, associating with the inhibition of JAK2/STAT1 activation. These findings provide evidence for the clinical use of YMJD for treatment of inflammatory pulmonary diseases like ALI.